Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
October 03, 2020
Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement